| Almost every pharmaceutical company in world often | | | | countries. |
| look at other countries like Africa, Asia, Latin America | | | | Due to the considerable increase in research, sales |
| and Eastern Europe in an attempt to further enhancing | | | | and production in these regions, CRO (CRO), the |
| pharmaceutical business and revenue and growth | | | | biotechnology and pharmaceutical companies today |
| hence to conduct clinical trials that are, by comparison, | | | | are challenged with problems of business ethics. Some |
| much more cost effective. The attraction of these | | | | countries are facing problems of corruption in clinical |
| emerging markets is recognized by many in the | | | | trials because of the need of logistical capacity and |
| industry, where a growing middle class will increase | | | | institutional data to be approved are taken for granted |
| spending on health care and where there are a | | | | or are more difficult to achieve this leads to remission |
| number of treatment-naive volunteers available to | | | | or back bribes to obtain the necessary approval to |
| recruit . | | | | conduct a particular clinical trial. |
| The conduct of clinical trials cost effective in those | | | | |